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This essay grew out of a presentation made to the medical staff of the
hospital where I practice. I am a pathologist and claim no special expertise
in the matter, however the topic of the morality of the use of methotrexate
in an ectopic pregnancy is of concern to me because I am a physician and a
Catholic. My institution is a secular one; I suspected that any attempt to
present the moral issues surrounding methotrexate baldly was likely to fail.
So I thought I'd approach the topic from a strictly medical perspective, do
a brief review of the current literature, and see how methotrexate faired as
a treatment alternative. Only after my "medical" presentation did I touch
on the moral issues.
Ectopic pregnancies are common: they occur about once in every
150 pregnancies. The overwhelming majority - over 96% - occur somewhere within the Fallopian tube. The remainder are extratubal , implanting
anywhere between the cervix and the interior of the abdomen. When an
ectopic is diagnosed it represents a medical situation of the most serious
nature. A few ectopics can be managed by close clinical follow up, as the
mother's body will sometimes reasorb the pregnancy. However, the
majority will require direct intervention. Even in those mothers who are
being followed the physician must be capable of intervening at the first
suggestion of an impending rupture, as a ruptured ectopic is a profound
medical emergency with an extremely high mortality. There is no question,
then, that the woman diagnosed with an ectopic pregnancy must be
aggressively managed.
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The traditional approach to management has been salpingectomy by
laparotomy. Today the procedure is done via laparoscopy unless the patient
is unstable (Kim & Fox , 1999), and has an essentially 100% cure rate
(Gabbe 1996). The embryonic child is not destroyed directly in this
procedure; she dies because she resides in the Fallopian tube which has
been removed, and cUlTently there is no way to keep her alive or reimplant
her in the mother's womb. In complete (a.k.a. "radical") salpingectomy the
entire tube is removed, leaving the remaining tube intact. In partial (a.k.a.
"conservative" or "segmental resection") salpingectomy the segment of
the tube containing the embryo is removed, and the remaining sections of
the tube are re-anastomosed. In both procedures, the mother does retain
fertility to a very high degree, as she has a remaining tube. Only in the
instance where the affected tube is completely removed and the other tube
has been previously damaged or removed is the mother's future fertility
significantly impaired by the salpingectomy procedure. Regardless of the
variant used, salpingectomy remains the "gold standard" of safety and
efficacy against which all other procedures are compared. Further, the
Church has long held that the procedure is morall y acceptable (ERD 1971 ,
no. 16; ERD 1994, no. 48). So, a treatment exists which is safe, highly
effective, and can be done with all the benefits of laparoscopic surgery.
Indeed, it is the standard against which all competing procedures are
compared. Finally, it is morally acceptable.

Recent Developments
Over the past two decades or so, a number of other surgical
approaches have been developed, including linear salpingotomy,
salpingostomy, fimbrial evacuation, and related variants. They are known
as "conservative procedures" because they have the common property of
being "tube sparing" meaning that the embryo is dissected or suctioned
out, usually through a small hole or linear incision. The tube is left largely
intact. The hypothetical benefit is the possibility of better future fertility
than in salpingectomy. These conservative procedures are safe, reasonably
effective, and represent standard therapeutic alternatives to traditional
salpingectomy in the U.S. However, though advertised as "better" than
salpingectomy because they impair future fertility less, the benefits appear
minuscule. If both tubes were present prior to the ectopic, there is
essentially no difference between salpingectomy and conservative
procedures in the likelihood of future intrauterine pregnancies. If there was
only one tube prior to the ectopic, there may be a slightly higher chance of
future intrauterine pregnancy after the tube sparing procedure than there
would be after a traditional salpingectomy, but there is also a higher chance
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of future ectopic pregnancy (Kim & Fox, 1999) due to scarring of the tube.
A very negative aspect of the conservative procedures is that they may be
unsuccessful in removing all the trophoblastic tissue, and the persistent
tissue then causes rupture and hemorrhage. For this reason, serial serum
quantitative B-HCGs must be followed after these procedures until they
decline to zero (this is true of salpingectomy as well) to ensure that there is
no residual viable trophoblastic tissue. The risk of persistent trophoblastic
tissue in the conservative procedures is between 3 and 17% (Kim & Fox
1999); this plus all other postoperative complications may be over 20%
(Gabbe 1996, Vermesh et ai, 1989; Sefer et aI, 1990). Thus, while this
essay is not primarily concerned with the conservative procedures, most of
the medical (and moral) issues which apply to methotrexate apply to these
procedures as well.
Methotrexate is a folic acid antagonist. Folic acid is necessary in the
synthesis of DNA and thus methotrexate effectively hinders rapidly
growing tissue by interfering with replicate DNA replication. Although it
now has numerous uses, methotrexate's first, and possibly still most
successful use is in the chemotherapeutic treatment of childhood
leukemias and lymphomas. Indeed, this is one of the miracles of modem
medicine: childhood leukemia was a death sentence until the introduction
of methotrexate. Now, it is a survivable disease, and children are alive and
well today who would have been dead for years but for the use of this drug.
Another cancer which methotrexate successfully treats is choriocarcinoma,
a malignancy of trophoblastic cells.
At around three to four days into the life of the embryonic child,
when she is at the "morula" (mulberry) stage, she divides into an "inner
cell mass" and an "outer cell mass". The inner mass will develop into the
embryo and fetus; the outer mass will develop into the trophoblast and,
eventually, the placenta. This division happens before she implants;
indeed it's a necessary thing for her to do as she is sailing down the
Fallopian tube to the womb, looking for a place to alight for the next few
months. It's sort of like an airplane lowering its landing gear while on final
approach, with the runway well in sight. The embryonic child lowers her
trophoblasts in preparation for landing. Well, anyway, trophoblasts can
become neoplastic. When they do so they usually develop as
choriocarcinoma, a highly malignant and fatal cancer. Many
choriocarcinomas are in no way associated with a pregnancy; they
originate in the ovary as a primary germ cell tumor. In those
choriocarcinomas that are related with a pregnancy the pregnancy was
rarely normal; the malignancy arises after a spontaneous miscarriage. Only
one out of 150,000 or more normal term pregnancies result in
choriocarcinoma. Regardless, trophoblasts (be they normal or abnormal)
are exquisitely sensitive to the effects of methotrexate, and that is why
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methotrexate turned this universally fatal malignancy into one which is
highly curable with an excellent long term prognosis.
Some twenty years ago, methotrexate began to be used in the
treatment of ectopic pregnancies. The rationale came out of its success in
the treatment of choriocarcinoma: by destroying the trophoblast of an
ectopic pregnancy, it might be successful in inducing a tubal abortion.
Since its initial trials methotrexate has become widely available in U.S .
hospitals as an alternative to surgery in select patients. It offers the
potential benefits of avoidance of surgery, maintenance of fertility, and
reduced costs. Not all women with ectopic pregnancies can be treated with
methotrexate; the American College of Obstetrics and Gynecology has
published guidelines indicating which patients are candidates (ACOG
Practice Bulletin No. 3, 1998). Some controversy exists regarding these
guidelines (Lipscomb, 1999; Barnhart et aI , 2000; Lipscomb et ai , 1998).
Regardless, recent estimates are that 30-40% of women with ectopic
pregnancies would be eligible for methotrexate therapy (Barnhart et ai,
2000).

Two Regimens Most Common
Many methotrexate regimens have been used in the treatment of
ectopic pregnancy. The two which seem to have emerged as the most
commonly used are the "single intramuscular dose" regimen (where repeat
1M doses are given only if the serum B-HCG doesn ' t fall by a specified
amount within a specified time) and the "multi dose regimen" (where four
scheduled doses are given, and then repeated if necessary). Success rates
for these regimens vary considerably. Many studies report success rates of
80-90%, generally about the same as the conservative surgical procedures
(Lipscomb et ai, 1998; Keefe, 1998; Hajenius, 1997; Stovall & Ling, 1993;
Stovall et aI , 1991). However, other authors report considerably poorer
outcomes, in the range of 65 % (Stika et ai, 1996). With the "single dose"
regimen, so many women require repeat doses that the term "single dose"
has been called "a misnomer" (Barnhart et ai, 2000) and "not effective
enough in eliminating tubal pregnancy..." (Hajenius, 2000). Some argue
that methotrexate shouldn ' t be used alone at all, but only in combination
with other abortifacients (Perdu et ai, 1998). This is significant insofar as
many practitioners currently consider the single dose regimen to be the
method of choice. In addition, an ectopic pregnancy is not considered
resolved until the serum quantitative B-HCG declines to zero due to the
possibility of residual trophoblastic tissue, as discussed above. With
methotrexate, the period of time that the patient must be followed with
serial blood draws and measurements is considerable longer than any of
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the surgical techniques, averaging 35 days post treatment and sometimes
taking up to seven weeks (Barnhart et aI, 2000).
Abdominal pain following methotrexate therapy is a significant
issue, occurring in over half of patients (Carr and Evans, 2000; Stika et aI,
1996). Some practitioners seem to feel that the pain is a consequence of the
prolonged tubal abortion which the drug is inducing. Regardless of the
cause, the continuing pain drives follow up evaluations that sometimes
become in themselves quite significant. Indeed, the need for a surgical
procedure to evaluate the persistent pain following methotrexate therapy
has been reported to be as high as 22% (Stika et aI, 1996). Methotrexate
therapy, especially in the single dose regimen, is theoretically cheaper than
a surgical treatment: that is, in fact, one of the "selling points". There is
some data to support this (Morlock, 2000). However, when prolonged
follow up, need for repeat dosing, not-infrequent need for surgical
intervention, and time lost from work is all factored in methotrexate may
not be cheaper, and may even be more expensive, than conservative
surgical procedures (Mol, 1999).
Another "selling point" of methotrexate therapy has been that the
prospects for future fertility are better than after surgical therapies. But
future fertility after treatment of an ectopic pregnancy seems to be no
worse than, but no better than, conservative surgical procedures (Keefe,
1998; Debby, 2000; Barnhart, 2000; Carr and Evans, 2000; Hajenius,
2000; Hajenius, 1997).
Extratubal ectopic pregnancies are rare, at 3-4% of all ectopics (Kim
and Fox , 1999). When they occur, however, they can require extensive
surgical procedures with potential significant morbidity, and which may
leave the woman sterile. Because of this, methotrexate treatment has been
held out as a valuable alternative procedure that can prevent the need for
extensive surgery. Although some authors consider methotrexate a first
line therapy in such an instance, the same authors note that "the success
rate of medical management is not truly known... Most likely, it is
substantially lower than the success rate of primary treatment of a tubal
gestation." (Barnhart et aI, 2000). Other authors state that "it is difficult to
make general recommendations" concerning methotrexate versus surgical
management of such patients due to the small numbers (Kim and Fox,
1999). At least one paper recommends "extreme caution" in the use of
single dose methotrexate in a specific type of extratubal ectopic, an
interstitial pregnancy (Gherman, 2000).
In summary, there is a great deal of enthusiasm in the obstetrical
literature concerning the use of methotrexate in ectopic pregnancy. One
wonders why, insofar as it seems to be, at best, a mediocre treatment
alternative: " ... No clear evidence favors methotrexate or salpingostomy as
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the treatment of choice. Successful treatment rates are nearly identical
among the two potions, as are rates of subsequent fertility ..." (Carr and
Evans, 2000).
The moral issues have been thoroughly covered elsewhere (May,
2000). Salpingectomy does not constitute a direct abortion because it does
not kill the child directly. Indeed, the intent is not to kill the child. The
intent, as mentioned above, is to remove the portion of tube in which the
child resides. The child dies as a tragic but unintended and unavoidable
consequence. Controversy among moral theologians about the use of
methotrexate seems to revolve around whether destruction of the
trophoblast by the drug constitutes a direct abortion, with at least some
authors concluding that it does not (Clark, 2000). The idea is that the
trophoblast is not the part of the embryo that develops into the fetus (the
"inner cell mass" mentioned above), but the part that develops into the
placenta (the "outer cell mass"). Therefore, if I follow the reasoning, since
the drug doesn't kill the embryo directly, just her landing gear, it is not a
direct abortion and is OK from a moral standpoint for use in the treatment
of the ectopic pregnancy. Perhaps. But it is worth noting that the
obstetrical literature unabashedly and unreservedly refers to the procedure
as a tubal abortion of the embryo, and the obstetrician authors don't seem
to give it a second thought. Indeed, methotrexate is frequently used in
combination with misoprostol for, well, routine elective abortions of
intrauterine pregnancies of less than 49 days' duration (Creinin, 2000;
Pymay & Creinin, 2000; Creinin 1998; Creinin, 1997). Interestingly,
another folic acid antagonist, which presumably worked via the same
mechanism as methotrexate, was used in the 1950s specifically to induce
therapeutic abortions in first trimester patients (Creinin, 2000). It is also
worth keeping in mind that the intrauterine device, and, sometimes,
injectable/implantable hormones and birth control pills, do not kill the
embryo directly; they create a hostile environment within the womb which
impedes successful implantation. In this context, though, they are often
considered abortifacients. Indeed, the abortion pill, mifepristone, doesn't
kill the embryo, or affect her directly in any way. It merely blocks the
effects of progesterone on the uterus, effects which the uterus needs to
support the embryo. Without progesterone, the uterus cannot support the
embryonic baby, and expels her (Creinin, 2000; Pymar & Creinin, 2000;
Schatz et ai , 1997). So, to suggest that methotrexate is not an abortifacient
because it only destroys the trophoblast, and not the "embryo proper" (if,
indeed, such a distinction can be legitimately made; I don't accept it)
seems to be splitting hairs just a little too fine. I believe that the reason the
obstetrical authors don't trouble themselves as to whether these various
drugs and devices cause direct abortions is because they know full well
that the intent is to cause an abortion . Never mind the mechanism. To my
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untrained and admittedly unsophi sticated mind, use of methotrexate can't
seem to reasonably be anything other than the intended direct abortion of
the implanted embryo as the means of treating the ectopic pregnancy.
Because I believe methotrexate to represent a direct abortion of the
embryo, and because the Catechism of the Catholic Church teaches that
direct, intended abortion is never morally acceptable (CCC #2270,227 1),
the use of methotrexate to treat an ectopic pregnancy would not seem
morall y admissible. Thi s is because (as the Catechi sm further teaches) a
good end - saving the mother's life - may not be obtained by an evil
means - the abortion of the embryonic child (CCC, # 1756). Further, as
the Church has long held, there is a safe and highly effective procedure
avai lable which is morall y acceptable in the form of salpingectomy.
Indeed, salpingectomy is more effective than methotrexate. Thus,
methotrexate as a therapeuti c alternati ve in the treatment of ectopic
pregnancy would seem inadmi ssible to me, a Catholic physician, on moral
grounds. Despite the continuing enthusiasm for the procedure in the
secul ar literature, it should seem hi ghly questionable to any physician on
medical grounds.
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